Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunoadsorption therapy for myasthenia gravis

N Shibuya1, T Sato, M Osame

  • 1Department of Neurology, Kawatana National Hospital, Nagasaki, Japan.

Journal of Neurology, Neurosurgery, and Psychiatry
|May 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Frameshift mutation in the collagen VI gene causes Ullrich's disease.

Annals of neurology·2001
Same author

Usefulness of transcutaneous Doppler jugular venous echo to predict pulmonary hypertension in COPD patients.

The European respiratory journal·2001
Same author

HLA-A*26, HLA-B*4002, HLA-B*4006, and HLA-B*4801 alleles predispose to adult T cell leukemia: the limited recognition of HTLV type 1 tax peptide anchor motifs and epitopes to generate anti-HTLV type 1 tax CD8(+) cytotoxic T lymphocytes.

AIDS research and human retroviruses·2001
Same author

Expression of vascular endothelial growth factor in tuberculous meningitis.

Journal of the neurological sciences·2001
Same author

Cytotoxic T-cell abundance and virus load in human immunodeficiency virus type 1 and human T-cell leukaemia virus type 1.

Proceedings. Biological sciences·2001
Same author

Phenotypes of X-linked Charcot-Marie-Tooth disease and altered trafficking of mutant connexin 32 (GJB1).

Journal of human genetics·2001

Immunoadsorption therapy using IM-TR effectively improved severe generalized myasthenia gravis symptoms in many patients. This treatment reduced acetylcholine receptor antibodies and induced long-term remission, especially in those with thymic hyperplasia.

Area of Science:

  • Neurology
  • Immunology
  • Medical Technology

Background:

  • Myasthenia gravis (MG) is a severe autoimmune neuromuscular disease.
  • Current treatments for severe MG can be insufficient, leading to persistent weakness.
  • Immunoadsorption offers a potential therapeutic avenue for refractory cases.

Purpose of the Study:

  • To evaluate the efficacy of immunoadsorption therapy using tryptophan-linked polyvinyl alcohol gel (IM-TR) in severe generalized myasthenia gravis.
  • To assess the impact of IM-TR on clinical symptoms and acetylcholine receptor (AChR) antibody levels.
  • To identify patient subgroups that may benefit most from this immunoadsorption approach.

Main Methods:

  • A multicenter trial involving 20 patients with severe generalized myasthenia gravis on prednisolone and azathioprine.

Related Experiment Videos

  • Standardized treatment protocol involving five IM-TR adsorption sessions within 10 days.
  • Monitoring of clinical weakness, AChR antibody titers, and adverse events.

    • Main Results:

    • 11 out of 20 patients showed pronounced improvement in myasthenic weakness and achieved long-term remission.
    • AChR antibody levels decreased by approximately 60% per plasma volume treated.
    • The treatment was particularly effective in patients with thymic hyperplasia, with no difference in antibody removal rates between thymic hyperplasia and thymoma.
    • No serious complications were observed across 100 procedures.

    Conclusions:

    • Immunoadsorption therapy with IM-TR is a safe and effective option for managing severe generalized myasthenia gravis, particularly in patients unresponsive to conventional therapies.
    • IM-TR demonstrates significant clinical benefit and reduces pathogenic autoantibodies.
    • The therapy shows promise for improving outcomes in refractory myasthenia gravis patients.